OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Inside the Clinic: Experts Highlight Molecular Complexities in MCL

May 13th 2022

Maher Albitar, MD, and Andre H. Goy, MD, share insights regarding molecular complexities in mantle cell lymphoma.

Dr. O'Malley on Racial and Economic Barriers to Screening in CRC

May 13th 2022

Denalee O'Malley, PhD, discusses racial and economic barriers to colorectal screening in colorectal cancer.

Dr. Vaishampayan on the Design of the PROBE Trial in RCC

May 13th 2022

Ulka Nitin Vaishampayan, MBBS, discusses the design of the phase 3 PROBE trial in advanced renal cell carcinoma.

Inside the Clinic: Experts Discuss Practical Aspects of Next-Generation Sequencing

May 12th 2022

Maher Albitar, MD, and Andre H. Goy, MD, discuss practical aspects of next-generation sequencing.

Dr. LoRusso on the Efficacy of BI 907828 in Solid Tumors

May 12th 2022

Patricia LoRusso, DO, discusses the efficacy observed of BI 907828 in solid tumors in a phase 1 trial.

Dr. Osman on the SELECT-MDS Trial in Higher-Risk Myelodysplastic Syndrome

May 12th 2022

Afaf E. Osman, MD, discusses the phase 3 SELECT-MDS trial in patients with higher-risk myelodysplastic syndrome.

Dr. Kroener on Utilizing Embryo Cryopreservation in Breast Cancer

May 12th 2022

Lindsay L. Kroener, MD, discusses fertility preservation in patients with breast cancer.

Dr. Lambertini on the Effect of GnRH Agonists on Ovarian Function in Breast Cancer

May 11th 2022

Matteo Lambertini, MD, discusses how GnRH agonists work to preserve ovarian function in premenopausal patients with breast cancer.

Dr. Khan on the Ideal Patients for GnRH Agonists in Breast Cancer

May 11th 2022

Zaraq Khan, MBBS, discusses which patients with breast cancer would be ideal candidates to receive treatment with a GnRH agonist for ovarian protection.

Dr. Ko on Unmet Needs in PD-L1–Negative TNBC

May 10th 2022

Heidi Ko, DO, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer.

Dr. Ruddy on the Use of GnRH Agonists in Breast Cancer

May 10th 2022

Kathryn Ruddy, MD, discusses the use of GnRH agonists in breast cancer.

Dr. Furman on Current Treatment Options in CLL

May 10th 2022

Richard R. Furman, MD, discusses current treatment options in chronic lymphocytic leukemia.

Dr. Heyman on the ALPINE Trial in CLL

May 10th 2022

Benjamin Heyman, MD, discusses the phase 3 ALPINE trial in chronic lymphocytic leukemia.

Dr. Ma on Utilizing Zanabrutinib in CLL

May 10th 2022

Shuo Ma, MD, PhD, discusses the utilization of zanubrutinib in chronic lymphocytic leukemia.

Dr. McArthur on the FDA Approval of Second-Line Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 6th 2022

Heather McArthur, MD, MPH, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki for second-line treatment in HER2-positive metastatic breast cancer.

Dr. Partridge on the Utilization of GnRH Agonists in Breast Cancer

May 6th 2022

Ann H. Partridge, MD, MPH, discusses the utilization of GnRH agonists to preserve ovarian function in premenopausal patients with breast cancer.

Dr. Spira on the Examination of RTX-240 in a Phase 1 Trial with Solid Tumors

May 6th 2022

Alexander I. Spira, MD, PhD, FACP, discusses the examination of RTX-240 in a phase 1 trial with solid tumors.

Dr. Verstovsek on the Future of ALK2 Inhibitors in Myelofibrosis

May 4th 2022

Srdan Verstovsek, MD, PhD, discusses the future of ALK2 inhibitors in myelofibrosis.

Dr. Obeid on the KATHERINE Trial in HER2-Positive Breast Cancer

May 4th 2022

Elias Obeid, MD, MPH, discusses the phase 3 KATHERINE trial in HER2-positive breast cancer.

Dr. Kalinsky on Updates from the TAILORx Trial in HR-Positive/HER2-Negative Breast Cancer

May 4th 2022

Kevin Kalinsky, MD, MS, discusses updates from the phase 3 TAILORx trial in patients with hormone receptor–positive or HER2-negative breast cancer with node-negative disease.